Q1 2019 Results presentation These documents are also available for viewing on the SEC website at www.sec.gov. Call Participants . I have read this warning and will not be using any of the contained product information for clinical purposes. Company Participants. AstraZeneca PLC. Pascal Soriot, Chief Executive Officer, commenting on the results said: “Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. — AstraZeneca reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Another strong top-line performance, with operating leverage supporting compelling growth in earnings Results in the first quarter were supported by Product Sales growth of 10% (14% at CER 1) to $5,465m, a reflection of the sustained performance of new medicines 2 (+77%, +83% at CER Cr.) Cancer drugs boost AstraZeneca results in Q1 April 26, 2019 April 20, 2020 Riding on the strong demand for its cancer drugs, AstraZeneca Plc ( NYSE: AZN ) on Friday reported its third consecutive quarter of top line growth. ... [Phonetic] quarter 2020 results. AstraZeneca PLC . AstraZeneca Plc topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of 4.7% in premarket hours on Thursday. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. SEC filings are those documents that we are required to file by virtue of our listing on Nasdaq. 25 July 2019 07:00 BST. 14 February 2020. AstraZeneca Plc has told the European Union it expects to deliver less than half the COVID-19 vaccines it was contracted to supply in the second quarter, an EU official told Reuters on Tuesday. Products sales rose 8% year-over-year to $6.25 billion. At 1312 GMT, AstraZeneca shares were down 2.3% at 7,448 pence. AstraZeneca PLC 24 October 2019 07:00 BST Year-to-date and Q3 2019 results Patients to benefit from further pipeline progress; sales-growth momentum driving operating leverage Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). Currency movements are expected to unfavorably impact product sales and … The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Together with this encouraging financial start to the year, our highly-productive and sustainable pipeline continued to deliver, notably with a regulatory approval for Lynparzain the EU for the treatment of metastatic breast cancer and approvals of Farxigain type-1 diabetes. It is a listed company and is a subsidiary of AstraZeneca Plc, UK. Company Participants. Our country sites can be located in the AZ Network. Pascal Soriot - CEO & Executive Director. Friday 14 February – Astrazeneca full-year results. PDF 12,602KB View online summary. Full-year and Q4 2019 results announcement. AstraZeneca will release results for the fourth-quarter (Q4) and the full year at 0700 GMT on Thursday December 11. AstraZeneca reported its second-quarter earnings results on July 25. AstraZeneca Plc topped market estimates for revenue and earnings in the second quarter of 2019, giving shares a lift of 4.7% in premarket hours on Thursday. Another strong performance from our new medicines accompanied impressive results in our key markets, … There are typically 2 dividends per year (excluding specials), and the dividend cover is approximately 1.3. Questions and Answers. Our country sites can be located in the AZ Network. Year-to-date and Q3 2019 results. AstraZeneca PLC . 26 April 2019 07:00 BST Q1 2019 Results. Back then, AstraZeneca attributed a 5% drop in quarterly sales of Bydureon Bcise (exenatide extended-release) to “year-end production constraints of [the] new Bcise device .” July 25, 2019 March 24, 2020. 24 October 2019 07:00 BST. There is currently 9 brokers rating AstraZeneca at Strong Buy, … Below are key highlights of the result: Revenue: The company’s revenue for the period declined from N242 billion in the first quarter of 2018, to N240 billion in Q1 2019… AstraZeneca PLC. 2019. … AstraZeneca delivered strong results in the year, in line with guidance that was reconfirmed during the year. 19 Mar. PDF 2,918KB. We encourage you to read the privacy policy of every website you visit. AstraZeneca PLC (AZN) Q4 2019 Earnings Call Transcript AZN earnings call for the period ending December 31, 2019. ET. PDF 1,417KB Full-year and Q4 2019 results presentation. David Fredrickson - EVP & President, Oncology Business. Virtual bus tour, Bank of America, Healthcare Bus Tour 2021 [management], Virtual conference, Carnegie, Nordic Healthcare Seminar [management]. Despite Astrazeneca’s Covid vaccine success its shares remain unchanged for the past year and down by a fifth from their peak in the summer. Contacted by Reuters, AstraZeneca did not deny what the official said, but a statement late in the day said the company was striving to increase productivity to deliver the promised 180 million doses. Please refer to your approved national product label (SmPC) for current product information. A year of significant innovation for patients; accelerating the strategic transition. British drugmaker AstraZeneca forecast revenue growth ... and fell short of analysts' expectations for fourth-quarter results. U.S. drugmaker Pfizer and BioNTech's <22UAy.f> experimental vaccine was shown to be more … Year-to-date and Q3 2019 results Patients to benefit from further pipeline progress; sales-growth momentum driving operating leverage Year-to-date Product Sales growth of 13% (17% at CER1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). July 25, 2019 March 24, 2020. Full-year and Q4 2019 results. AstraZeneca’s Q2 results beat market expectations. Full-year 2020 results clinical trials appendix, Full-year 2020 financial results: Pascal Soriot, Full-year 2020: AstraZeneca financial results, Year-to-date and Q3 2020 results - webcast replay, Year-to-date and Q3 2020 results announcement, Year-to-date and Q3 2020 results presentation, Year-to-date and Q3 2020 results clinical trials appendix, Year-to-date and Q3 2020 results: José Baselga and Mene Pangalos, Year-to-date and Q3 2020: AstraZeneca financial results, Leading in sustainability - webcast replay, Audio replay of Farxiga’s DAPA-HF Investor Conference Call at ESC, H1 2020 Results: Continued growth and ongoing COVID-19 response, First-quarter 2020 results - Webcast replay, First-quarter 2020 results clinical trials appendix, CEO Pascal Soriot reflects on AstraZeneca's first-quarter 2020 results, Full-year and Q4 2019 results announcement, Full-year and Q4 2019 results presentation, Full-year and Q4 2019 results clinical trials appendix, 2019: A year of innovation for patients and the planet, Investor science conference call ASH 2019 Presentation, Investor conference science conference call – ASH 2019 audio replay, Investor science conference call ACR 2019 Presentation, Investor science conference call - ACR 2019 audio replay, Investor science conference call ASN 2019 Presentation, Investor science conference call - ASN 2019 audio replay, Year-to-date and Q3 2019 Results announcement, Year-to-date and Q3 2019 Results presentation, Year-to-date and Q3 2019 Results clinical trials appendix, David Fredrickson & Ruud Dobber reflect on AstraZeneca's Year-to-date and Q3 2019 Results, Investor science conference call: European Society for Medical Oncology (ESMO) Congress 2019, CEO Pascal Soriot reflects on AstraZeneca's H1 2019 Results, Audio replay of trastuzumab deruxtecan Investor conference call, Collaboration on trastuzumab deruxtecan Investor conference call presentation, Full-Year 2018 Results clinical trials appendix, Year-end webcast for investors and analysts on China and Emerging Markets Webcast Replay, Year-end webcast for investors and analysts on China and Emerging Markets Presentation, Year-End Investor & Analyst Webcast, China and Emerging Markets video, AHA Scientific Sessions 2018 - Investor Science Conference Call Presentation, Year-To-Date and Q3 2018 Results Announcement, Year-To-Date and Q3 2018 Results Presentation, Year-To-Date and Q3 2018 Clinical Trials appendix, 2018 ASCO Annual Meeting - Investor Event - plenary presentation - a leading, diversified oncology business, Audio recording of plenary presentation - A leading, diversified oncology business, 2018 ASCO Annual Meeting - Investor Event - Breakout 1 - Sales & Marketing execution, Audio recording of breakout 1 - Sales & Marketing execution, 2018 ASCO Annual Meeting - Investor Event - Breakout 2 - Lynparza lifecycle; MRK collaboration, Audio recording of breakout 2 - Lynparza lifecycle; MRK collaboration, 2018 ASCO Annual Meeting - Investor Event - Breakout 3 - Next-gen DNA damage response and tumour drivers, Audio recording of breakout 3 - Next-gen DNA damage response and tumour drivers, 2018 ASCO Annual Meeting - Investor Event - Breakout 4 - Next-gen Immuno-Oncology, ASCO 2018 Investor Event - Breakout 4 - Next-gen Immuno-Oncology, 2018 ASCO Annual Meeting - Investor and analyst planner and information pack, Full-Year 2017 Results investor presentation, Full-Year 2017 Results Clinical trials appendix, Late-stage pipeline webcast - Presentation, Late-stage pipeline webcast - Epidemiology data, Year to date and Q3 2017 Results announcement, Year to date and Q3 2017 clinical trials appendix, Year to date and Q3 2017 Results investor presentation, Year to date and Q3 2017 Results transcript, AstraZeneca Investor Science Event at ERS 2017 presentation, AstraZeneca Investor Science Event at ESMO 2017 presentation, AstraZeneca Investor Science Event at 2017 ASCO Annual Meeting, Full-Year and Q4 2016 Results announcement, Full-Year and Q4 2016 Results presentation, Full-Year and Q4 2016 Results Clinical trials appendix, Late-stage pipeline investor science webcast presentation, Year-to-date and Q3 2016 Results announcement, Year-to-date and Q3 2016 Clinical trials appendix, Year-to-date and Q3 2016 Results presentation, Year-to-date and Q3 2016 Results transcript, ERS Investor science webcast presentation, DNA Damage Response analyst science event, AstraZeneca Investor Science Event at ASCO 2016, Full-Year and Q4 2015 Results presentation, Fourth quarter and Full-Year Results 2015 press release, J.P. Morgan Healthcare Conference 2016 presentation, Acerta Investor conference call presentation, Acerta Investor conference call transcript, ACR Investor science conference call transcript, ACR Investor science conference call presentation, ZS Pharma Investor conference call presentation, H1 results 2015 press release & pipeline update, ASCO 2015 Investor science event presentation, ASCO 2015 Investor science event biographies, Q1 results 2015 press release & pipeline update, ACC 2015 Investor science conference call presentation, Q4 and full year results 2014 presentation, Q4 and full year results 2014 press release & development pipeline, Q4 and full year results 2014 clinical trials appendix, J.P. Morgan Healthcare Conference presentation, Core therapeutic areas presentation – Luke Miels, Emerging markets/Japan presentation – Mark Mallon, Pipeline: Respiratory, inflammation & autoimmunity presentation – Bing Yao, Pipeline: Cardiovascular & metabolic disease presentation – Elisabeth Björk, Pipeline: Oncology presentation – Susan Galbraith/Mohammed Dar, Late-stage development presentation – Briggs Morrison, Innovative medicines and early development presentation – Mene Pangalos, Q3 and nine months results 2014 presentation, Q3 and nine months results 2014 press release, Q3 and nine months results 2014 pipeline table, Q3 and nine months results 2014 clinical trial programmes summary, Q2 and half year results 2014 presentation, Q2 and half year results 2014 press release, Q2 and half year results 2014 clinical trial programmes summary, Strategic Transaction with Almirall in Respiratory Disease presentation, Q1 results 2014 development pipeline table, Q4 and full year results 2013 press release, Q4 and full year results 2013 development pipeline table, Q4 and full year results 2013 presentation, Q4 and full year results 2013 clinical programmes summary, J.P. Morgan Healthcare Conference development pipeline table, J.P. Morgan Healthcare Conference webcast, Q3 and nine months results 2013 presentation, Q3 and nine months results 2013 press release, Q2 and half year results 2013 presentation, Q2 and half year results 2013 press release, Q2 and half year results 2013 – Pascal Soriot (CEO) script, Q2 and half year results 2013 – Simon Lowth (CFO) script, Q4 and full year results 2012 press release, Q4 and full year results 2012 development pipeline table, Q4 and full year results 2012 presentation, Q4 and full year results 2012 – Pascal Soriot opening script, Q4 and full year results 2012 – Briggs Morrison script, Q4 and full year results 2012 – Simon Lowth script, Q4 and full year results 2012 – Pascal Soriot closing script, Fostamatinib analyst briefing presentation, Q3 and nine months results 2012 presentation, Q3 and nine months results 2012 analyst call script, Q2 and half year results 2012 presentation, Q2 and half year results 2012 – Simon Lowth (Interim CEO) script, Q2 and half year results 2012 – Tony Zook (Executive Vice-President Commercial Operations) script, Q2 and half year results 2012 – Julie Brown (Interim CFO) script, AstraZeneca business update – Simon Lowth (Interim CEO) script, Q1 results 2012 – David Brennan (CEO) script, Q1 results 2012 – Simon Lowth (CFO) script, Q4 and full year results 2011 presentation, Q4 and full year results 2011 – David Brennan (CEO) script, Q4 and full year results 2011 Simon Lowth (CFO) script, Q4 and full year results 2011 – Martin Mackay (President R&D) script, Q4 and full year results 2011 – Tony Zook (EVP Commercial Operations) script, 30th Annual J.P. Morgan Healthcare Conference presentation, Q2 and half year results 2011 press release, Q2 and half year results 2011 presentation, Q2 and half year results 2011 clinical trial programmes summary, Q4 and full year results 2010 press release, Q4 and full year results 2010 development pipeline table, Q2 and half year results 2010 presentation, Q2 and half year results 2010 press release, Q2 and half year results 2010 clinical trial programmes summary, Full-year 2020 results - Roadshows and conferences. Pfizer records its share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions––net commencing from August 1, 2019. There are a number of reasons for this, Mould says. Cancer drugs boost AstraZeneca results in Q1 April 26, 2019 April 20, 2020 Riding on the strong demand for its cancer drugs, AstraZeneca Plc ( NYSE: AZN ) on Friday reported its third consecutive quarter of top line growth. Notably, shares suffered a heavy fall when it last missed expectations with its Q4 2019 results a year ago. AstraZeneca rose 1.7 per cent, among the top boosts to the STOXX 600, after the Covid-19 vaccine developer beat quarterly product sales estimates and forecast 2021 revenue growth. Check out why AstraZeneca share price is up today. AstraZeneca first identified the production constraints affecting the Type II diabetes treatment at the time of its fourth quarter results, in February 2019. Pascal Soriot, Chief Executive Officer, commenting on the results said: “Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. There are a number of reasons for this, Mould says. At 1312 GMT, AstraZeneca shares were down 2.3% at 7,448 pence. Contents: Prepared Remarks. You are about to access AstraZeneca historic archive material. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Q1 2019 Results clinical trials appendix, Adrian Kemp Download Annual Report in PDF format 2020 2019 2018 2017 2016 Standalone ... Quarterly Results of AstraZeneca Pharma (in Rs. Before I hand over the call to Pascal Soriot at AstraZeneca… The Directors confirm that to the best of our knowledge: AstraZeneca provides this link as a service to website visitors. AstraZeneca earnings consensus: what to expect Dec. 11, 2019. 14 February 2020 7:00 GMT. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. European healthcare stocks were up 0.5 per cent, while technology shares added 1.0 per cent and were among the top sectoral gainers. AstraZeneca share price is rising today after the company reported better-than-expected quarterly results yesterday. Download our Annual Report and Form 20-F Information 2020. AstraZeneca PLC. CEO Pascal Soriot reflects on AstraZeneca's first-quarter 2020 results. Pascal Soriot - CEO & Executive Director. PUBLISHED 24 October 2019. Prepared Remarks: Operator. AstraZeneca PLC. Full-year and Q4 2019 results. AstraZeneca PLC AZN is scheduled to report first-quarter 2019 results on Apr 26.. Full-year and Q4 2019 results. AstraZeneca PLC (NASDAQ:AZN) Q3 2019 Earnings Conference Call October 24, 2019 7:00 AM ET. Total revenue increased 13% year-over-year to $5.8 … AstraZeneca plc AZN is scheduled to report fourth-quarter and full-year 2019 results on Feb 14. Therefore, Pfizer recorded its share of two months of the JV’s earnings generated in third-quarter 2019 in Pfizer’s operating results in fourth-quarter 2019. Full-year 2020 results - Roadshows and conferences. Requests may be made by writing to: Company Secretary First-half Product Sales growth of 12% (17% at CER(1) ) to $11,183m included an acceleration in second-quarter Product Sales to $5,718m (+14%, +19% at CER). Veeva ID: Z4-25396Date of next review: August 2022. – In the US Alibaba, PepsiCo and Kraft-Heinz quarterly results. AstraZeneca PLC Q1 2019 Earnings Call April 26, 2019, 7:00 a.m. AstraZeneca PLC (NASDAQ:AZN) Q1 2019 Earnings Conference Call April 26, 2019 7:00 AM ET. 25 July 2019 . Important notice for users In addition, the company will hold a virtual roadshow during which it will discuss the annual results in further detail on Friday December 12. Virtual bus tour, UBS, Nordic Investor Tour [management] Add to Calendar; Download available. Pascal Soriot, Chief Executive Officer, commenting on the results said: “With AstraZeneca growing at pace, our sales guidance has been upgraded for the second consecutive quarter. AstraZeneca plc (AZN) Presents At 2019 ASH Annual Meeting - Slideshow. Zscaler will host a conference call for analysts and investors to discuss its third quarter fiscal 2019 earnings results and outlook for its fourth quarter of fiscal 2019 and full year fiscal 2019 today at 1:30 p.m., Pacific time (4:30 p.m. Eastern time). With over half of Total Revenue coming from the fast-growing new medicines 1 , the Company leveraged its revenue growth to make further progress in profitability, while the strategy of sustainable growth through innovation brought numerous further benefits for patients. AstraZeneca PLC (NASDAQ:AZN) Q1 2019 Earnings Conference Call April 26, 2019 7:00 AM ET. AstraZeneca however maintained core EPS guidance for 2019 in the range of $3.50 to $3.70. PDF 2,918KB. H1 2019 Results . Get detailed AstraZeneca stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. In Oncology, Tagrisso, Imfinziand Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta and Fasenra also grew strongly. Feb. 14, 2020. In Oncology, Tagrisso, Imfinziand Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta and Fasenra also grew strongly. Patients to benefit from further pipeline progress; sales-growth momentum driving operating leverage. The shares are up by more than 1.13%, becoming the best performing in the FTSE 100 index. AstraZeneca's first-quarter sales beat estimates on aggressive push into cancer drugs Published Fri, Apr 26 2019 6:23 AM EDT Updated Fri, Apr 26 2019 6:23 AM EDT In the first quarter, AstraZeneca grew sales by 17% at constant currencies to $6.31 billion, 7% ahead of industry watchers’ expectations. Our Core Operating Profit almost doubled, demonstrating strong operating-margin improvement. AstraZeneca’s Q2 results beat market expectations. ET. Despite Astrazeneca’s Covid vaccine success its shares remain unchanged for the past year and down by a fifth from their peak in the summer. I have read this warning and will not be using any of the contained product information for clinical purposes. Please refer to your approved national product label (SmPC) for current product information. — Oncology sales advanced by 29% and respiratory sales grew by 13%. AstraZeneca has continued its impressive growth, with product sales up 18 per cent in the third quarter to $6,132million. The stock is already up 6.39% on the day and is trading close to $42.91. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Video . Financial statements and reports for AstraZeneca plc (AZN) Ordinary US$0.25 including annual reports and financial results for the last 5 years. This statement relates to and is extracted from the Annual Report. Continuing strong top-line performance underpins confidence in sustainable growth First-half Product Sales growth of 12% (17% at CER 1) to $11,183m included an acceleration in second-quarter Product Sales to $5,718m (+14%, +19% at CER). Pascal Soriot - CEO. AstraZeneca PLC. AstraZeneca however maintained core EPS guidance for 2019 in the range of $3.50 to $3.70. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. AstraZeneca Pharma India Q3 net profit declines 21% at Rs 21 crore 06.11.2020 AstraZeneca Standalone September 2020 Net Sales at Rs 209.48 crore, up 0.48% Y-o-Y This website is intended for people seeking information on AstraZeneca's worldwide business. It is repeated here solely for the purpose of complying with DTR 6.3.5.It is not connected to the information presented in this announcement or in the Company's fourth quarter and full year results 2018 announcement that was published on 14 February 2019.. Veeva ID: Z4-25396Date of next review: August 2022. Year-to-date and Q3 2019 Results. The recently-announced collaboration with Daiichi Sankyo also broadened an exciting Oncology portfolio with a potentially-transformative cancer treatment that could benefit patients around the world. Full-year and Q4 2019 results Presentation, conference call and webcast for investors and analysts 14 February 2020. We encourage you to read the privacy policy of every website you visit. H1 2019 Results. Important notice for users The company’s earnings beat estimates in each of … AstraZeneca PLC (NASDAQ:AZN) Q3 2019 Earnings Conference Call October 24, 2019, 07:00 ET Company Participants Pascal Soriot - CEO David Fredrickson - … You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca PLC 14 February 2020 7:00 GMT Full-year and Q4 2019 results A year of significant innovation for patients; accelerating the strategic transition AstraZeneca delivered a year of strong revenue growth, supported by the launch of new medicines1 and further good progress on its pipeline, with several approvals and data readouts. The third quarter again saw all three therapy areas and every sales region … AstraZeneca has generated $1.75 earnings per share over the last year and currently has a price-to-earnings ratio of 50.7. The stock is already up 6.39% on the day and is trading close to $42.91. AstraZeneca share price live updates on The Economic Times. 14 February 2020 7:00 GMT. Good morning and good afternoon, welcome ladies and gentlemen to AstraZeneca's Q1 2019 Results Conference Call and Webcast for investors and analysts. AstraZeneca AZN beat the Zacks Consensus Estimate for both earnings and sales in the second quarter of 2019 and also raised ... than-expected results. AstraZeneca PLC (AZN Quick Quote AZN - Free Report) is scheduled to report third-quarter 2019 results on Oct 24.. This website is intended for people seeking information on AstraZeneca's worldwide business. The previous Astrazeneca plc dividend was 69.6p and it went ex 7 months ago and it was paid 6 months ago. AstraZeneca … It's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China. AstraZeneca reported its second-quarter earnings results on July 25. -Full-year results from RELX and Coca-Cola HBC-Trading update from Ted Baker-Astrazeneca full-year results. ... for 2019. Year-to-date Product Sales growth of 13% (17% at CER 1) to $17,315m included third-quarter Product Sales of $6,132m (+16%, +18% at CER). AstraZeneca PLC 2019 Q4 - Results - Earnings Call Presentation. Speaking at a Financial Times online conference on healthcare on Monday, AstraZeneca senior executive team member, Ruud Dobber, said the first set of efficacy data from a large-scale study made him optimistic that AstraZeneca too would be able to follow up on positive results from early-stage trials. It's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China. They contain mainly financial information. Company Participants. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. The drug maker also recorded strong sales growth in emerging markets and China, with the revenues up 14% and 21% respectively, helping to total revenue hit $5.49 billion. Full-year 2020 results - Roadshows and conferences. The … A year of significant innovation for patients; accelerating the strategic transition. AstraZeneca PLC AstraZeneca Plc raised its product sales forecast for 2019 on Thursday after second-quarter results beat analysts' expectations, thanks to strong sales … The next Astrazeneca plc dividend went ex 14 days ago for 137.4p and will be paid in 18 days. The consensus estimate was for earnings of $0.29 per share on revenues of $5.5 billion. PDF 2,622KB Full-year and Q4 2019 results clinical trials appendix.